Generation Bio Raises $100 Million Series B to Finance Non-Viral Gene Therapy Program Post author:Sam Post published:February 26, 2018 Post category:BioPharma Cambridge, Massachusetts-based Generation Bio closed on a $100 million Series B financing today. Source: BioSpace You Might Also Like Autonomic Tech Announces Expanded Indication In Europe (CE Mark) For Disabling Migraine With Pulsante SPG Microstimulator System March 9, 2017 Why This Seattle Biotech Could be an M&A Target January 18, 2018 Prime Therapeutics Urges Caution On Mandates Of Abuse-Deterrent Formulations Of Opioids Citing Value Concerns July 20, 2017
Autonomic Tech Announces Expanded Indication In Europe (CE Mark) For Disabling Migraine With Pulsante SPG Microstimulator System March 9, 2017
Prime Therapeutics Urges Caution On Mandates Of Abuse-Deterrent Formulations Of Opioids Citing Value Concerns July 20, 2017